IMPORTANCE Distant recurrence following preoperative chemoradiotherapy and resection in patients with gastroesophageal adenocarcinoma is common. Adjuvant chemotherapy may improve survival.
G astroesophageal (GE) cancer is an important and increasing cause of cancer burden globally. 1 Despite advancements in multimodality therapy, GE cancer remains a leading cause of cancer deaths worldwide owing to its aggressive nature and poor prognosis. Multiple trials have demonstrated improved outcomes in patients with GE cancer treated with preoperative chemoradiotherapy (CRT) followed by surgical resection. [2] [3] [4] [5] [6] In particular, the phase 3 randomized Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study (CROSS) trial showed that preoperative CRT doubled the median survival from 24 to 49 months when compared with resection alone. 5 The survival benefit was most pronounced in patients with esophageal squamous cell carcinoma but was less definitive for those with adenocarcinoma (P = .07). In particular, approximately one-third of patients developed distant recurrence. 7 The reduced duration and dose of systemic chemotherapy in preoperative CRT may have limited the regimen's efficacy to prevent distant failure. For patients with GE adenocarcinoma, additional chemotherapy may reduce the risk of distant recurrence and improve survival. Currently, there are few data to support the addition of adjuvant chemotherapy (AC) to preoperative CRT and resection for GE adenocarcinoma. Limited institutional studies have shown that the use of adjuvant therapy in patients with residual disease was associated with a modest survival benefit. 8, 9 In this study, we compared overall survival between AC and postoperative observation (POB) in patients with GE adenocarcinoma following preoperative CRT and resection.
Methods

Database and Patient Population
We identified patients with adenocarcinoma (International Classification of Diseases for Oncology, third edition [ICD-O-3], morphological codes 821, 822, 825, 826, 831, 848, 849, and 857) involving the distal esophagus (ICD-O-3 topographical codes C15.2 and C15.5) or gastric cardia (C16.0) in the National Cancer Database (NCDB) participant user data file between years 2006 and 2013. The NCDB is a national cancer registry receiving information from more than 1500 Commission-on-Cancer-accredited cancer programs in the United States. Approximately 70% of incident cancer cases in the United States are captured in the NCDB. 10 This study was approved by the institutional review board of the University of Texas Southwestern. Informed consent of study patients was waived by the review board due to the retrospective nature of the study. We included patients older than 18 years with clinical stage T1N1-3M0 or T2-4N0-3M0 according to the seventh edition of the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) TNM staging manual. Only patients who received preoperative CRT and underwent a curative-intent resection were included. We excluded patients who underwent a palliative resection aimed at controlling symptoms or alleviating pain.
We abstracted patient information (patient age, sex, race, ethnicity, Charlson/Deyo comorbidity score, income, and insurance type) and tumor data (year of diagnosis, location, histologic type, grade, clinical and pathological UICC/AJCC TNM stages, tumor extension, and involved lymph nodes). In the NCDB, comorbidity conditions are mapped from up to 10 secondary diagnosis codes. 11, 12 Patients who received a diagnosis between 2006 and 2009 were staged initially using the sixth edition of the UICC/AJCC TNM staging manual. We adjusted their staging to reflect the stage categories of the manual's seventh edition. A more detailed description of these adjustments can be found elsewhere. [13] [14] [15] Treatment data on the type of resection, the time from diagnosis to resection, and receipt of preoperative and/or postoperative chemotherapy and radiation were available. Per the NCDB participant user data file data dictionary, pre-and postoperative chemotherapy reflect the receipt of at least 2 courses of chemotherapy pre-and postoperatively, respectively. The NCDB data dictionary also specifies that treatment information recorded in the NCDB database pertain to first-course treatment only. Thus, treatment given for disease progression or recurrence is excluded. In addition, we abstracted data on number of lymph nodes examined, resection margins, and early postoperative outcomes including length of hospital stay, 30-day unplanned readmissions, and 30-day and 90-day mortality.
Statistical Analysis Conditional Landmark Analysis
We used conditional landmark analysis to account for the immortal time bias in the AC group. 16 The bias reflects the fact that patients in the AC group must have survived the postoperative period, as well as the period during which they received at least 2 cycles of AC. As such, we included in our analysis only patients who survived at least 90 days postoperatively. Our choice of landmark time at postoperative 90 days relates to this period's significance as a surgical performance and quality of care metric.
17,18
Estimation Findings In this propensity score-matched analysis of 10 086 patients using the National Cancer Database, the median overall survival was significantly longer in patients treated with adjuvant chemotherapy compared with patients who underwent observation.
Meaning
In patients with gastroesophageal adenocarcinoma, adjuvant chemotherapy following preoperative chemoradiotherapy and resection may be warranted.
margin (3.7%), number of lymph nodes examined (5.2%), postoperative length of stay (14.2%), and unplanned 30-day readmissions (3.7%). We used baseline information, as well as treatment allocation variables, to generate 20 imputed data sets.
Propensity Score Matching
We used propensity score matching to compare overall survival between the AC and POB groups. We estimated, in each imputed data set, the propensity score, that is, the conditional probability of receiving AC, using a multivariable logistic regression model. In this model, we explored clinically relevant variables, as well as factors associated either with the receipt of AC or with overall survival to estimate the propensity scores. These variables included age, sex, race/ethnicity, comorbidity score, income, insurance type, facility type, time from diagnosis to resection, tumor location, grade, clinical T and N stages, pathological T and N stages, number of lymph nodes examined, resection margins, length of stay, and 30-day unplanned readmissions. The latter 2 variables were included to account for selection bias related to the fact that patients with postoperative complications are less likely to receive AC. The C statistic for the logistic regression models ranged between 0.73 and 0.74 among the 20 imputed data sets. The estimated propensity scores from all imputed data sets were then combined using the mean of the individual estimates in each data set, according to the Rubin rule.
19,20(pp75-81)
Within the 2 tumor location categories, distal esophagus and gastric cardia, a 1-to-5 (AC to POB) matching by propensity score, without replacement, was performed using the nearest neighbor method within a caliper of 0.1. 21 We performed matching separately within each tumor location stratum primarily because surgical resections are expectedly less variable within each tumor location stratum; therefore, postoperative complications are more likely to be homogenous. In addition, specific details about the type of resections are lacking in the NCDB. The choice of a 1-to-5 matching ratio was determined by maximizing this ratio while maintaining a 90% match rate in the AC group. Propensity score matching was performed using the Matching package in R, version 3.3.1 (R Foundation). 22, 23 Balance in the baseline covariates after matching was examined using standardized differences. 24 An absolute standardized difference less than 0.1 implies an adequate match. Balance in baseline variables was also evaluated using the likelihood ratio test following conditional logistic regression modeling of the management approach (AC, POB) in the matched data.
Survival Data Analysis
We used Kaplan-Meier curves to estimate the overall survival from the time of diagnosis in the AC and POB groups in the matched data. A log-rank test stratified on matched patients was used to compare survival in both groups. The association between postoperative management approach, AC vs POB, and overall survival was evaluated using a Cox proportional hazards model stratified on matched patients. The assumption of proportional hazards was evaluated by examining the scaled Schoenfeld residuals.
We evaluated for heterogeneity in treatment effects within baseline covariates using tests for interaction. 25 We also estimated the treatment effect using a Cox regression model within each level of each covariate. The following covariates were evaluated: tumor location, pathologic T stage, pathologic N stage, and resection margin status.
Sensitivity Analyses
One of the criticisms of propensity score matching is the reduction of sample size, which can lead to a decrease in power.
To address this possibility, we evaluated the association between the postoperative management plan and overall survival in the entire patient cohort using propensity score weighting. The weights were constructed to estimate the mean treatment effect in the AC group, analogous to the treatment effect estimated using matching by propensity score.
26(pp239-255)
The effect of adjuvant chemotherapy compared with postoperative observation did not appreciably change in direction or significance (data not shown); therefore, we report only the results of the primary analysis, matching by propensity score. We also conducted a sensitivity analysis to quantify the effect of the unmeasured postoperative complications, which is not available in the NCDB and may affect overall survival, on the association between the postoperative management approach (AC vs POB) and overall survival. 27, 28 To do so, we assessed the extent to which the proportion of postoperative complications needs to be imbalanced between AC and POB to eliminate the treatment effect of AC (ie, the upper bound of the 95% confidence interval [CI] for the hazard ratio [HR] crosses 1). We reestimated the HR and its 95% CI, over a range of hypothetical proportions, elicited from the literature and expert opinion, of postoperative complications in the AC and POB groups-such that the proportion of complications is assumed to be higher in the POB group-and for various estimates of the association between postoperative complications and overall survival.
2,5,29
In this study, significance level was .05 for all hypothesis tests. Apart from propensity score matching, all analyses were conducted using STATA, version 14.
Results
Baseline Characteristics in the Original (Unmatched) Data
Between 2006 and 2013, we identified 11 130 adult patients with adenocarcinoma of the distal esophagus or gastric cardia who completed preoperative CRT and curative-intent resection ( Figure 1) . A total of 10 086 patients were included in the analysis after the exclusion criteria were applied; 6317 (63%) patients had tumor involving the distal esophagus and 3769 (37%) patients had disease at the gastric cardia. There were 9272 (92%) patients in the POB group and 814 (8%) patients in the AC group. The 
Overall Survival in the Matched Data
Following the 5-to-1 matching by propensity score, 732 patients in the AC group were matched to 3660 patients in the POB group, yielding a 90% match rate. The baseline covariates between the 2 treatment groups in the matched data were adequately matched as evidenced by small standardized differences (0.04) and nonsignificant likelihood ratio tests (Table) . The median follow-up of the entire matched cohort was 27 months (interquartile range [IQR], 17-44 months). For most patients (3559 [82%]), the time from diagnosis to resection was less than 5 months. Median duration of preoperative therapy was 5.6 weeks (IQR, 5.1-6.0 weeks) in both groups. The median overall survival was 34 months (95% CI, 32-35 months) in the POB group and 40 months (95% CI, 36-46 months) in the AC group (stratified log-rank P < .001) (Figure 2) . The overall survival rates at 1, 3, and 5 years were 88%, 47%, and 34% in the POB group, and 94%, 54%, and 38% in the AC group, respectively. The addition of chemotherapy in the adjuvant setting was associated with improved overall survival compared with observation only (HR, 0.79; 95% CI, 0.72-0.88).
There was no significant evidence of heterogeneity of treatment effect among the tumor-specific covariate levels (P≥.10 for interaction among all examined covariates) (Figure 3) . In the subgroup analysis, AC was associated with improved overall survival compared with POB in most examined baseline tumor-specific covariates. The survival benefit was largest, although not statistically significant, in patients with pathologic complete response (ypT0N0; HR, 0.57; 95% CI, 0.28-1.13)-a relevant finding given that this patient group has a 23% risk of recurrence. 30 
Sensitivity Analysis
The results from the sensitivity analysis performed to quantify the effect of postoperative complications, an unmeasured confounder, on the association between AC and survival are presented in eTable 2 in the Supplement. The survival benefit of AC over POB remained significant over a range of hypothetical estimates of postoperative complications. In other words, postoperative complications would need to be as high as 50% in the POB group and as low as 5% in the AC group as well as the HR for postoperative complications on survival to be at least 1.5-all of which are reasonably extreme valuesfor the impact of unmeasured postoperative complications to nullify the treatment effect of AC on overall survival (ie, render the hazard ratio for AC vs POB not significant).
Discussion
Multiple trials have shown that preoperative CRT and resection for GE cancer improves the rate of complete pathologic response, local tumor control, and margin-negative resection along with overall survival.
3-6 However, few data exist regarding the use of adjuvant chemotherapy after resection. In this study, we showed that adjuvant therapy was associated with improved overall survival compared with POB in patients with GE adenocarcinoma who completed preoperative CRT and curative-intent resection. This survival benefit was nearly uniform across patient subgroups. The rationale for adjuvant chemotherapy is to decrease the rate of distant recurrence to improve survival. The risk of distant disease recurrence is considerable in patients undergoing preoperative CRT and resection for GE cancer, with nearly 50% of patients demonstrating distant recurrence in some trials. 31 The reduced chemotherapy dose and/or the protracted chemotherapy course in preoperative CRT regimens may partly explain more frequent recurrence and worse survival observed in patients undergoing observation. We found that AC was used in only 8% after preoperative CRT and resection. Patients receiving AC demonstrated higher-risk features including advanced disease stage, greater positive resection margin rate, and lower rates of pathologic complete response. The limited data available regarding the use of any postoperative therapy, including chemotherapy, following preoperative CRT and resection consists of retrospective studies and the administration of postoperative therapy was feasible and suggested a potential survival benefit. However, the singlearm designs and small sample sizes of these studies preclude a definitive conclusion regarding the superiority (or inferiority) of adjuvant therapy over POB. Our findings reflect current practice patterns at NCDB institutions during the study period rather than treatment within a clinical trial setting. As such, there is likely substantial heterogeneity in patient selection, preoperative regimens, patient follow-up, and radiotherapy and surgical quality control. These factors may dilute the estimated treatment effect between AC and POB, reflecting an average effect of a mixture of AC regimens.
Although the NCDB lacks details about the specific chemotherapy received, we assume that the regimens were variable throughout the study period. Cisplatin and fluorouracil were more likely to have been administered in the early years of this study because those agents were frequently used in preoperative CRT trials for esophageal cancer, 3,4,31,35 whereas carboplatin and paclitaxel were more frequent following the publication of the CROSS trial in 2012. 5 The difference in the type of systemic chemotherapy and the exposure period in the preoperative setting may have an impact on the effect of postoperative adjuvant chemotherapy on overall survival. However, there was no differential treatment effect between the period prior to the year 2012 and the period 2012 to 2013 (P of the interaction term = .32), suggesting that the probable wide use of CROSS regimens did not drastically change the treatment effect of AC on survival. Notably, our study cannot account for treatment of recurrent disease. Possible variations in second-line treatment between AC and POB may affect survival, and, as a result, our conclusions. However, the impact of this is likely minor. Extrapolating from data on unresectable GE cancer, prognosis for recurrent disease is invariably dismal, and available treatment regimens unfortunately do not impart meaningful differences in survival.
36,37
The estimated effect of AC on overall survival is subject to selection bias and immortal time bias given that the study was observational. We used matching by propensity score to account for the former and conditional landmark analysis to mitigate the effects of the latter. Importantly, we addressed selection bias related to postoperative complications in the following ways: (1) we excluded patients who died within 90 days postoperatively, (2) we included postoperative length of stay and unplanned readmission in estimating the propensity score, and (3) we matched by propensity score within the strata of tumor location. We also showed using sensitivity analysis that the survival benefit of AC was robust to large ranges of imbalance in an unmeasured confounder such as postoperative complications. Performance status is also a potential source of selection bias that is not collected in NCDB.
Limitations
The main limitation of this study is its retrospective nature. We used propensity scoring and conditional landmark analysis to mitigate selection bias and immortal time bias. Another important limitation is that the NCDB lacks detailed information on certain variables, such as detailed chemotherapy regimens, that would provide more granular data for analysis.
Conclusions
The findings from this study support adding chemotherapy in the adjuvant setting to improve overall survival in patients with GE adenocarcinoma who complete preoperative CRT and resection. These findings, while not confirmatory, provide compelling motivation to explore the potential benefit of adju- .69
Marker size is proportional to the precision of the hazard ratio (HR) estimate. CRT indicates chemoradiotherapy; P values are for interaction.
vant chemotherapy in a randomized clinical trial. Given the moderate difference in overall survival between patients who receive adjuvant chemotherapy and those who receive POB, as well as the lack of data on the type and period of adjuvant chemotherapy, a 2-arm phase 2 trial design using recurrencefree survival as a primary end point is an appealing first step. The success of such a trial will depend primarily on the choice of preoperative CRT and adjuvant chemotherapy regimens, the feasibility of delivering these regimens, and their tolerability in this patient population. Optimal multimodality treatment followed by surgical resection results in cure for less than half of patients with operable adenocarcinoma of the lower esophagus or gastroesophageal junction. This is true whether the adjunctive therapy is neoadjuvant chemotherapy, perioperative chemotherapy, or neoadjuvant chemoradiotherapy. Therefore, it is reasonable to question whether additional treatment beyond current standards of care might increase the proportion of patients cured. In this issue of JAMA Oncology, Mokdad and colleagues, 1 in a propensity score-matched analysis based on a large National Cancer Database cohort, examine the effects of adjuvant chemotherapy following chemoradiotherapy and surgery for resectable gastroesophageal adenocarcinoma. They found that patients treated with adjuvant chemotherapy had improved overall survival compared with those who did not receive adjuvant treatment (median overall survival, 40 vs 34 months; hazard ratio, 0.79; 95% CI, 0.72-0.88; P < .001). Based on these findings, a randomized clinical trial of adjuvant chemotherapy vs observation following neoadjuvant chemoradiotherapy and surgical resection is proposed to provide a definitive answer to this question.
The data set explored by Mokdad et al 1 is large, containing more than 10 000 patients, of whom 814 (8%) received adjuvant chemotherapy following neoadjuvant chemoradiotherapy. The small percentage of patients treated with adjuvant chemotherapy is reassuring; neoadjuvant chemoradiotherapy and surgery followed by adjuvant chemotherapy is not a treatment approach endorsed by current national or international guidelines. 2,3 In the unadjusted cohort, patients treated with adjuvant chemotherapy had more advanced disease measured using T and N stage, and had more frequent positive resection margins. They were also more likely to have private medical insurance, an adequate number of lymph nodes resected, and a shorter time to diagnosis than the group who did not receive adjuvant therapy. The authors note that all significant measured differences between the 2 groups were adjusted for in the propensity-matched analysis. Even so, it is possible that the second set of variables listed could reflect unmeasured confounders in the quality of care between the 2 groups that could affect overall survival. Also unknown are the preoperative chemotherapy regimens with which patients were treated, the dose intensity of these regimens, and the dosage and fractionation of radiotherapy received. Notwithstanding these potential weaknesses, the results of Mokdad et al 1 demonstrate a small but potentially clinically relevant absolute benefit in overall survival of 4% at 3 years for patients treated with adjuvant chemotherapy following chemoradiotherapy plus surgical resection. As most recurrent gastroesophageal cancers occur within 3 years of surgery, this possibly represents an increase in the proportion of patients cured. However, these findings can only be confirmed in a randomized clinical trial. Current national and international guidelines suggest that evidence-based treatment for patients with operable esophageal and gastroesophageal junctional adenocarcinoma may include neoadjuvant or perioperative chemotherapy, or neoadjuvant chemoradiotherapy, followed by surgical resection.
2,3
Since publication of the CROSS trial in 2012, neoadjuvant chemoradiotherapy with weekly carboplatin and paclitaxel plus radiotherapy has been widely adopted as a standard of care. 4 Concerns regarding the lack of systemic efficacy of the lowintensity chemotherapy in CROSS have been alleviated, in part, by data from a long-term follow-up of the study, which demonstrated a reduction in the occurrence of distant metastases for up to 2 years following surgery in patients treated on the experimental arm of the trial. 5 However, the results of Mokdad et al 1 appear to indicate that even after contemporary neoadjuvant chemoradiotherapy, survival outcomes could be improved by the addition of further systemic chemotherapy. This is unsurprising because for most patients, gastroesophageal adenocarcinoma is a systemic disease. 
